On a disclosed basis, annual sales went from KRW 17 billion in 2022 to KRW 21.9 billion in 2023 (up 29.3%), fell to KRW 15.9 billion in 2024 (down 27.5%), and recovered to KRW 19.3 billion in 2025 (up 21.4%). 2023 was the largest year in the period and 2024 the smallest.
The company attributed the 2025 sales increase to genomic-analysis government projects. The same filing cited higher facility and headcount investment for new-business entry as the reason losses widened.
Operating losses were KRW 5.15 billion in 2022, KRW 4.34 billion in 2023, KRW 9.11 billion in 2024 and KRW 12.5 billion in 2025, a loss in each of the four years from 2022 to 2025. The operating margin improved from -30.3% in 2022 to -19.8% in 2023, then fell to -57.3% in 2024 and -64.6% in 2025.
Losses grew in 2025 even as sales rose, suggesting new-business investment costs rose faster than revenue. Net loss attributable to controlling shareholders went from KRW 7.78 billion in 2022 to KRW 16.4 billion in 2025.
Total net loss, including non-controlling interests, was KRW 8.08 billion in 2022, a different figure from the controlling-shareholder number. Operating cash flow swung from a KRW 910 million inflow in 2022 to outflows of KRW 5.03 billion in 2023, KRW 6.78 billion in 2024 and KRW 9.39 billion in 2025.
The debt-to-equity ratio rose to 117.3% in 2024 and fell to 79.4% in 2025, with year-end 2025 total equity of KRW 68.6 billion, all attributable to controlling shareholders, and total liabilities of KRW 54.4 billion.
Quarterly, operating losses were KRW 3.86 billion in Q3 2025, KRW 1.44 billion in Q4 2025, KRW 4.92 billion in Q1 2026, KRW 4.16 billion in Q2 2026 and KRW 5.18 billion in Q3 2026.
Net income attributable to controlling shareholders was KRW 8.01 billion in Q2 2026, a turn to profit, and a loss of KRW 9.74 billion in Q3 2026, a turn back to loss. The four quarters from Q4 2025 to Q3 2026 total KRW 11.2 billion in losses attributable to controlling shareholders.